LIVIVO - Search results -

Search results

Result 1 - 10 of total 492

Search options

Book: Alzheimer's disease - modernizing concept, biological diagnosis and therapy

Hampel, Harald / Carillo, Maria C.

14 tables

(Advances in biological psychiatry ; 28)

2012

Author's details	vol. ed.: H. Hampel ; M. C. Carillo
Series title	Advances in biological psychiatry ; 28
Collection
Keywords	Alzheimerkrankheit
Subject	Alzheimer-Krankheit ; Alzheimersche Krankheit ; Alzheimer-Demenz ; Morbus Alzheimer ; Greisenblödsinn ; Alzheimer's Disease
Language	English
Size	V, 193 S. : Ill., graph. Darst.
Publisher	Karger
Publishing place	Basel u.a.
Publishing country	Switzerland
Document type	Book
HBZ-ID	HT017217127
ISBN	978-3-8055-9802-6 ; 3-8055-9802-5 ; 9783805598033 ; 3805598033
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2012 A 2480	order for loan	Magazin

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Book: Alzheimer-Demenz

Auer, Stefanie / Hampel, Harald

klinische Verläufe, diagnostische Möglichkeiten, moderne Therapiestrategien

2003

Author's details	hrsg. von Harald Hampel ... Unter Mitarbeit von S. Auer
Keywords	Alzheimerkrankheit
Subject	Alzheimer-Krankheit ; Alzheimersche Krankheit ; Alzheimer-Demenz ; Morbus Alzheimer ; Greisenblödsinn ; Alzheimer's Disease
Language	German
Size	IX, 500 S. : Ill., graph. Darst.
Publisher	Wiss. Verl.-Ges
Publishing place	Stuttgart
Publishing country	Germany
Document type	Book
HBZ-ID	HT013577902
ISBN	3-8047-1928-7 ; 978-3-8047-1928-6
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2003 A 653	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Amyloid-β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms.

Hampel, Harald

Journal of Alzheimer's disease : JAD

2013 Volume 33 Suppl 1, Page(s) S79–86

Abstract: Amyloid-β (Aβ) deposition in the brain is one of the key pathological features of Alzheimer's disease (AD). Neither traditional clinical-pathological studies nor modern in vivo biomarker investigations of brain amyloid load, however, could reveal a ... ...

Abstract	Amyloid-β (Aβ) deposition in the brain is one of the key pathological features of Alzheimer's disease (AD). Neither traditional clinical-pathological studies nor modern in vivo biomarker investigations of brain amyloid load, however, could reveal a convincing relationship between brain Aβ load and cognitive deficits and decline in patients with AD. Evidence suggests that pathophysiological Aβ dysregulation and accumulation are very early events that precede the onset of cognitive impairment reaching a plateau at the clinical stage of the beginning dementia syndrome. Therefore, research efforts have focused on the role of Aβ in asymptomatic older adults: the results of combined amyloid-PET and neuropsychological studies show a modest but significant correlation between brain fibrillar amyloid load and various subtle cognitive deficits, most notably in challenging episodic associative memory tasks. In order to elucidate the pathophysiological link between cognition and Aβ, a number of combined functional neuroimaging studies have been performed, resulting in early and complex functional alterations in cognitively relevant neural networks such as the default mode network and the largely overlapping episodic memory networks. Multimodal studies using amyloid-tracing imaging methods and neurodegeneration biomarkers strongly suggest that neural network discoordination is specifically related to Aβ-mediated functional and potentially reversible disruption of synaptic plasticity rather than a direct consequence to neurodegenerative pathological processes. These pathophysiological processes and mechanisms may dynamically and non-linearly evolve through fully reversible adaptive compensatory stages and through reactive decompensatory stages into fully irreversible neurodegenerative stages of AD.
MeSH term(s)	Aging/metabolism ; Aging/pathology ; Aging/psychology ; Alzheimer Disease/diagnostic imaging ; Alzheimer Disease/metabolism ; Alzheimer Disease/pathology ; Alzheimer Disease/psychology ; Amyloid beta-Peptides/metabolism ; Brain/diagnostic imaging ; Brain/metabolism ; Brain/pathology ; Cognition ; Cognition Disorders/diagnostic imaging ; Cognition Disorders/metabolism ; Cognition Disorders/pathology ; Cognition Disorders/psychology ; Humans ; Radionuclide Imaging
Chemical Substances	Amyloid beta-Peptides
Language	English
Publishing date	2013
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	1440127-7
ISSN	1875-8908 ; 1387-2877
ISSN (online)	1875-8908
ISSN	1387-2877
DOI	10.3233/JAD-2012-129003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6084: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.

Hampel, Harald / Elhage, Aya / Cho, Min / Apostolova, Liana G / Nicoll, James A R / Atri, Alireza

Brain : a journal of neurology

2023 Volume 146, Issue 11, Page(s) 4414–4424

Abstract: Excess accumulation and aggregation of toxic soluble and insoluble amyloid-β species in the brain are a major hallmark of Alzheimer's disease. Randomized clinical trials show reduced brain amyloid-β deposits using monoclonal antibodies that target ... ...

Abstract	Excess accumulation and aggregation of toxic soluble and insoluble amyloid-β species in the brain are a major hallmark of Alzheimer's disease. Randomized clinical trials show reduced brain amyloid-β deposits using monoclonal antibodies that target amyloid-β and have identified MRI signal abnormalities called amyloid-related imaging abnormalities (ARIA) as possible spontaneous or treatment-related adverse events. This review provides a comprehensive state-of-the-art conceptual review of radiological features, clinical detection and classification challenges, pathophysiology, underlying biological mechanism(s) and risk factors/predictors associated with ARIA. We summarize the existing literature and current lines of evidence with ARIA-oedema/effusion (ARIA-E) and ARIA-haemosiderosis/microhaemorrhages (ARIA-H) seen across anti-amyloid clinical trials and therapeutic development. Both forms of ARIA may occur, often early, during anti-amyloid-β monoclonal antibody treatment. Across randomized controlled trials, most ARIA cases were asymptomatic. Symptomatic ARIA-E cases often occurred at higher doses and resolved within 3-4 months or upon treatment cessation. Apolipoprotein E haplotype and treatment dosage are major risk factors for ARIA-E and ARIA-H. Presence of any microhaemorrhage on baseline MRI increases the risk of ARIA. ARIA shares many clinical, biological and pathophysiological features with Alzheimer's disease and cerebral amyloid angiopathy. There is a great need to conceptually link the evident synergistic interplay associated with such underlying conditions to allow clinicians and researchers to further understand, deliberate and investigate on the combined effects of these multiple pathophysiological processes. Moreover, this review article aims to better assist clinicians in detection (either observed via symptoms or visually on MRI), management based on appropriate use recommendations, and general preparedness and awareness when ARIA are observed as well as researchers in the fundamental understanding of the various antibodies in development and their associated risks of ARIA. To facilitate ARIA detection in clinical trials and clinical practice, we recommend the implementation of standardized MRI protocols and rigorous reporting standards. With the availability of approved amyloid-β therapies in the clinic, standardized and rigorous clinical and radiological monitoring and management protocols are required to effectively detect, monitor, and manage ARIA in real-world clinical settings.
MeSH term(s)	Humans ; Alzheimer Disease/complications ; Antibodies, Monoclonal, Humanized/therapeutic use ; Amyloid beta-Peptides/metabolism ; Brain/metabolism ; Amyloid ; Amyloidogenic Proteins
Chemical Substances	Antibodies, Monoclonal, Humanized ; Amyloid beta-Peptides ; Amyloid ; Amyloidogenic Proteins
Language	English
Publishing date	2023-06-09
Publishing country	England
Document type	Review ; Journal Article
ZDB-ID	80072-7
ISSN	1460-2156 ; 0006-8950
ISSN (online)	1460-2156
ISSN	0006-8950
DOI	10.1093/brain/awad188
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui II Zs.26: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Thesis: Ein- und zweidimensionale Gelelektrophorese von postmortalem zerebralem Gewebe bei schizophrenen Erkrankungen

Hampel, Harald

Nachweis immunomodulatorisch wirksamer Proteine

1995

Author's details	vorgelegt von Harald-Jürgen Hampel
Language	German
Size	IV, 125 S. : Ill.
Document type	Book ; Thesis
Thesis / German Habilitation thesis	München, Univ., Diss., 1996
HBZ-ID	HT007375356
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
96 D 3753	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention.

Hampel, Harald

International psychogeriatrics

2012 Volume 24 Suppl 1, Page(s) S10–7

Abstract: The development of therapies for Alzheimer's disease (AD) presents numerous challenges for physicians, researchers, and the pharmaceutical industry, with many drug candidates showing promise at one stage of clinical research only to fall at the next ... ...

Abstract	The development of therapies for Alzheimer's disease (AD) presents numerous challenges for physicians, researchers, and the pharmaceutical industry, with many drug candidates showing promise at one stage of clinical research only to fall at the next hurdle. A great number of drugs with a variety of targets and clusters of mechanisms are currently in various stages of basic and clinical investigation. However, these hypothesis-derived agents may be tested much too late in the chronically progressive disease process to demonstrate meaningful effects or outcomes, mirroring the clinical syndromal scenario in which the underlying pathophysiological disease condition is frequently diagnosed extremely late. Moreover, the complexity of the disease calls for developments and improvements in study designs and methods modeled for different target populations and disease stages (e.g. asymptomatic to prodromal to syndromal). New integrated concepts and models of disease pathophysiology, use of validated and qualified biomarkers, outcomes and endpoints, particularly the development of a surrogate outcome, may allow targeting of characteristic mechanism-derived therapies of specifically affected biological systems at different time-points in the disease process, providing increasing opportunities for early and preventative intervention. A core set of feasible diagnostic and predictive biomarkers is already validated and in the process of standardization; however, continued and intensified research efforts will likely reveal a variety of novel biomarkers that grasp the complexity of the underlying disease process. In the future, trials of drugs to modify and prevent AD may embrace enrichment strategies and maybe be stratified by disease stage, genetic factors as well as by disease endophenotypes.
MeSH term(s)	Alzheimer Disease/drug therapy ; Alzheimer Disease/physiopathology ; Alzheimer Disease/prevention & control ; Biomarkers/analysis ; Disease Progression ; Ginkgo biloba ; Humans ; Phytotherapy ; Plant Extracts/therapeutic use
Chemical Substances	Biomarkers ; Plant Extracts ; Ginkgo biloba extract (19FUJ2C58T)
Language	English
Publishing date	2012-08
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1038825-4
ISSN	1741-203X ; 1041-6102
ISSN (online)	1741-203X
ISSN	1041-6102
DOI	10.1017/S1041610212000579
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2621: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 513: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Online: Alzheimer's Disease - Modernizing Concept, Biological Diagnosis and Therapy

Hampel, Harald

(Advances in Biological Psychiatry ; 28)

2012

Author's details	H. Hampel ... (vol. eds.)
Series title	Advances in Biological Psychiatry ; 28
Language	English
Size	1 Online-Ressource (VI, 194 S)
Document type	Book ; Online
Note	How current biomarkers are modernizing the diagnosis of Alzheimer's disease
ISBN	9783805598026 ; 9783805598033 ; 3805598025 ; 3805598033
Database	Special collection on veterinary medicine and general parasitology

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: A Systematic Review of Clinical Practice Guidelines for Alzheimer's Disease and Strategies for Future Advancements.

Tahami Monfared, Amir Abbas / Phan, N T Nhan / Pearson, Isobel / Mauskopf, Josephine / Cho, Min / Zhang, Quanwu / Hampel, Harald

Neurology and therapy

2023 Volume 12, Issue 4, Page(s) 1257–1284

Abstract: Introduction: Alzheimer's disease (AD) is a disease continuum from pathophysiologic, biomarker and clinical perspectives. With the advent of advanced technologies, diagnosing and managing patients is evolving.: Methods: A systematic literature review ...

Abstract	Introduction: Alzheimer's disease (AD) is a disease continuum from pathophysiologic, biomarker and clinical perspectives. With the advent of advanced technologies, diagnosing and managing patients is evolving. Methods: A systematic literature review (SLR) of practice guidelines for mild cognitive impairment (MCI) and AD dementia was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). This systematic literature review (SLR) aimed to summarize current clinical practice guidelines for screening, testing, diagnosis, treatment and monitoring in the AD continuum. The results of this SLR were used to propose a way forward for practice guidelines given the possible introduction of biomarker-guided technology using blood- or plasma-based assays and disease-modifying treatments (DMTs) targeted for early disease. Results: 53 clinical practice guidelines were identified, 15 of which were published since 2018. Screening for asymptomatic populations was not recommended. Biomarker testing was not included in routine diagnostic practice. There was no consensus on which neurocognitive tests to use to diagnose and monitor MCI or AD dementia. Pharmacologic therapies were not recommended for MCI, while cholinesterase inhibitors and memantine were recommended for AD treatment. Discussion: The pre-2018 and post-2018 practice guidelines share similar recommendations for screening, diagnosis and treatment. However, once DMTs are approved, clinicians will require guidance on the appropriate use of DMTs in a clinical setting. This guidance should include strategies for identifying eligible patients and evaluating the DMT benefit-to-risk profile to facilitate shared decision-making among physicians, patients and care partners. Conclusion: Regular evidence-based updates of existing guidelines for the AD continuum are required over the coming decades to integrate rapidly evolving technologic and medical scientific advances and bring emerging approaches for management of early disease into clinical practice. This will pave the way toward biomarker-guided identification and targeted treatment and the realization of precision medicine for AD.
Language	English
Publishing date	2023-06-01
Publishing country	New Zealand
Document type	Journal Article
ISSN	2193-8253
ISSN	2193-8253
DOI	10.1007/s40120-023-00504-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The foundation and architecture of precision medicine in neurology and psychiatry.

Hampel, Harald / Gao, Peng / Cummings, Jeffrey / Toschi, Nicola / Thompson, Paul M / Hu, Yan / Cho, Min / Vergallo, Andrea

Trends in neurosciences

2023 Volume 46, Issue 3, Page(s) 176–198

Abstract: Neurological and psychiatric diseases have high degrees of genetic and pathophysiological heterogeneity, irrespective of clinical manifestations. Traditional medical paradigms have focused on late-stage syndromic aspects of these diseases, with little ... ...

Abstract	Neurological and psychiatric diseases have high degrees of genetic and pathophysiological heterogeneity, irrespective of clinical manifestations. Traditional medical paradigms have focused on late-stage syndromic aspects of these diseases, with little consideration of the underlying biology. Advances in disease modeling and methodological design have paved the way for the development of precision medicine (PM), an established concept in oncology with growing attention from other medical specialties. We propose a PM architecture for central nervous system diseases built on four converging pillars: multimodal biomarkers, systems medicine, digital health technologies, and data science. We discuss Alzheimer's disease (AD), an area of significant unmet medical need, as a case-in-point for the proposed framework. AD can be seen as one of the most advanced PM-oriented disease models and as a compelling catalyzer towards PM-oriented neuroscience drug development and advanced healthcare practice.
MeSH term(s)	Humans ; Precision Medicine ; Alzheimer Disease ; Neurology ; Neurosciences ; Psychiatry
Language	English
Publishing date	2023-01-13
Publishing country	England
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	282488-7
ISSN	1878-108X ; 0378-5912 ; 0166-2236
ISSN (online)	1878-108X
ISSN	0378-5912 ; 0166-2236
DOI	10.1016/j.tins.2022.12.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1442: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 53: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease.

Lista, Simone / Hampel, Harald

Expert review of neurotherapeutics

2017 Volume 17, Issue 1, Page(s) 47–57

Abstract: Introduction: Synaptic dysfunction and degeneration are early fundamental pathophysiological characteristics of Alzheimer's disease (AD). In addition, synaptic depletion closely correlates with clinical disease severity. Biomarkers that may track ... ...

Abstract	Introduction: Synaptic dysfunction and degeneration are early fundamental pathophysiological characteristics of Alzheimer's disease (AD). In addition, synaptic depletion closely correlates with clinical disease severity. Biomarkers that may track synaptic dysfunction in AD are eagerly awaited. Areas covered: Here, we reviewed the significance of the post-synaptic protein neurogranin - particularly enriched in dendritic spines - as a biomarker of early synaptic dysfunction in AD. We also examined its role as a marker to predict disease progression. Expert commentary: Current evidence indicates that neurogranin may serve as a mechanism-of-action biomarker aiding the in vivo investigation of AD-related pathophysiological pathways. Its use may support the development of targeted therapeutic interventions tailored to the individual patient, i.e. 'molecularly' targeted therapies, according to the evolving precision medicine paradigm.
MeSH term(s)	Alzheimer Disease/metabolism ; Alzheimer Disease/physiopathology ; Amyloid beta-Peptides/metabolism ; Biomarkers ; Disease Progression ; Humans ; Neurogranin
Chemical Substances	Amyloid beta-Peptides ; Biomarkers ; Neurogranin (132654-77-4)
Language	English
Publishing date	2017-01
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2112534-X
ISSN	1744-8360 ; 1473-7175
ISSN (online)	1744-8360
ISSN	1473-7175
DOI	10.1080/14737175.2016.1204234
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6155: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito